Autopsy report · NCT04668521

Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection

“cohort C looked at feasibility of genetics \& protein to evaluate risk with a family hx of cancer or associated variant. Since few patients show these factors, this approach would not yield sufficient information to make inferences”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months after it had already started.
• Ran for about 3 years 7 months before it stopped.
• 215 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Aspira Women's Health

Sponsor type

Industry

Conditions

Adnexal Mass; Germline BRCA1 Gene Mutation; Germline BRCA2 Gene Mutation; Hereditary Breast and Ovarian Cancer

Interventions

OVA360

Participants

215

Sites

1

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.